PortfoliosLab logo
DNA vs. PLTR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DNA and PLTR is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.5

Performance

DNA vs. PLTR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Palantir Technologies Inc. (PLTR). The values are adjusted to include any dividend payments, if applicable.

-100.00%0.00%100.00%200.00%300.00%400.00%500.00%NovemberDecember2025FebruaryMarchApril
-98.06%
414.04%
DNA
PLTR

Key characteristics

Sharpe Ratio

DNA:

-0.68

PLTR:

5.83

Sortino Ratio

DNA:

-1.08

PLTR:

4.73

Omega Ratio

DNA:

0.89

PLTR:

1.65

Calmar Ratio

DNA:

-0.78

PLTR:

8.93

Martin Ratio

DNA:

-1.09

PLTR:

29.89

Ulcer Index

DNA:

71.34%

PLTR:

14.09%

Daily Std Dev

DNA:

113.40%

PLTR:

72.35%

Max Drawdown

DNA:

-99.10%

PLTR:

-84.62%

Current Drawdown

DNA:

-98.69%

PLTR:

-9.50%

Fundamentals

Market Cap

DNA:

$456.72M

PLTR:

$252.78B

EPS

DNA:

-$10.54

PLTR:

$0.19

PS Ratio

DNA:

2.01

PLTR:

88.22

PB Ratio

DNA:

0.64

PLTR:

50.52

Total Revenue (TTM)

DNA:

$189.10M

PLTR:

$2.23B

Gross Profit (TTM)

DNA:

$138.44M

PLTR:

$1.78B

EBITDA (TTM)

DNA:

-$316.36M

PLTR:

$245.67M

Returns By Period

In the year-to-date period, DNA achieves a -20.16% return, which is significantly lower than PLTR's 49.12% return.


DNA

YTD

-20.16%

1M

17.89%

6M

-3.92%

1Y

-74.80%

5Y*

N/A

10Y*

N/A

PLTR

YTD

49.12%

1M

22.21%

6M

151.40%

1Y

419.48%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DNA vs. PLTR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNA
The Risk-Adjusted Performance Rank of DNA is 1515
Overall Rank
The Sharpe Ratio Rank of DNA is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of DNA is 1212
Sortino Ratio Rank
The Omega Ratio Rank of DNA is 1616
Omega Ratio Rank
The Calmar Ratio Rank of DNA is 66
Calmar Ratio Rank
The Martin Ratio Rank of DNA is 2525
Martin Ratio Rank

PLTR
The Risk-Adjusted Performance Rank of PLTR is 9999
Overall Rank
The Sharpe Ratio Rank of PLTR is 100100
Sharpe Ratio Rank
The Sortino Ratio Rank of PLTR is 9999
Sortino Ratio Rank
The Omega Ratio Rank of PLTR is 9898
Omega Ratio Rank
The Calmar Ratio Rank of PLTR is 100100
Calmar Ratio Rank
The Martin Ratio Rank of PLTR is 9999
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DNA vs. PLTR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Palantir Technologies Inc. (PLTR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for DNA, currently valued at -0.68, compared to the broader market-2.00-1.000.001.002.003.00
DNA: -0.68
PLTR: 5.83
The chart of Sortino ratio for DNA, currently valued at -1.08, compared to the broader market-6.00-4.00-2.000.002.004.00
DNA: -1.08
PLTR: 4.73
The chart of Omega ratio for DNA, currently valued at 0.89, compared to the broader market0.501.001.502.00
DNA: 0.89
PLTR: 1.65
The chart of Calmar ratio for DNA, currently valued at -0.78, compared to the broader market0.001.002.003.004.005.00
DNA: -0.78
PLTR: 10.37
The chart of Martin ratio for DNA, currently valued at -1.09, compared to the broader market-5.000.005.0010.0015.0020.00
DNA: -1.09
PLTR: 29.89

The current DNA Sharpe Ratio is -0.68, which is lower than the PLTR Sharpe Ratio of 5.83. The chart below compares the historical Sharpe Ratios of DNA and PLTR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.008.00NovemberDecember2025FebruaryMarchApril
-0.68
5.83
DNA
PLTR

Dividends

DNA vs. PLTR - Dividend Comparison

Neither DNA nor PLTR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

DNA vs. PLTR - Drawdown Comparison

The maximum DNA drawdown since its inception was -99.10%, which is greater than PLTR's maximum drawdown of -84.62%. Use the drawdown chart below to compare losses from any high point for DNA and PLTR. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-98.69%
-9.50%
DNA
PLTR

Volatility

DNA vs. PLTR - Volatility Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 32.07% compared to Palantir Technologies Inc. (PLTR) at 28.34%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than PLTR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%35.00%40.00%45.00%NovemberDecember2025FebruaryMarchApril
32.07%
28.34%
DNA
PLTR

Financials

DNA vs. PLTR - Financials Comparison

This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Palantir Technologies Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items